Article Contents ::

Details About Generic Salt ::  Propafen

Main Medicine Class:: Antiarrhythmic   

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

 

Drugs Class ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Indications for Drugs ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Dose ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Contraindication ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Precautions ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Side Effects ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Mode of Action ::  

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Interactions ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Drug Assesment ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Storage/Management ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Drug Notes ::

Rythmol
Class: Antiarrhythmic

 

Action Reduces fast inward current carried by sodium ion in the Purkinje fibers, and to a lesser extent myocardial fibers.

 

Indications Treatment of documented life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia). unlabeled use(s): Treatment of supraventricular tachycardias including atrial fibrillation and flutter and arrhythmias associated with Wolff-Parkinson-White syndrome.

 

Contraindications Uncontrolled CHF; cardiogenic shock; sinoatrial, atrioventricular and intraventricular disorders of impulse generation and conduction (eg, sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker; bradycardia; marked hypotension; bronchospastic disorders; manifest electrolyte imbalance; coadministration of cisapride; and known hypersensitivity to the drug.

 

Route/Dosage

Individually titrate dose based on response and tolerance. ADULTS: PO 150 mg q 8 hr initially, increasing at a min of 3- to 4-day intervals to 225 mg q 8 hr and, if necessary, to 300 mg q 8 hr.

 

Interactions

Cisapride: Contraindicated because of increase risk of life-threatening cardiac arrhythmias. Cyclosporine, desipramine, digoxin, metoprolol, propranolol, theophylline, warfarin: Propafenone may increase plasma concentrations of these agents, increasing the risk of side effects and toxicity. Cimetidine, quinidine, ritonavir: May increase propafenone plasma concentrations, potentially increasing pharmacologic and adverse effects. Rifamycins (ie, rifabutin, rifapentine): May decrease propafenone plasma concentrations, decreasing the therapeutic effect. Local anesthetics: May increase the risk of CNS side effects.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Angina; atrial fibrillation; bradycardia; bundle branch block; chest pain; CHF; first and second degree AV block; hypotension; increased QRS duration; intraventricular conduction delay; palpitations; premature ventricular contractions; tremor; wide complex tachycardia. CNS: Anxiety; ataxia; drowsiness; dizziness; fatigue; headache; insomnia; loss of balance; weakness. DERM: Rash. EENT: Blurred vision; dry mouth; tinnitus; unusual taste. GI: Abdominal pain and cramps; anorexia; constipation; diarrhea; flatulence; nausea; vomiting. HEMA: Agranulocytosis; granulocytopenia; thrombocytopenia. hepa: Hepatocellular injury. META: Edema. RESP: Dyspnea. OTHER: Diaphoresis; fever; joint pain; syncope.

 

Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Because of the increased risk of impaired renal and hepatic function, use with caution. Arrhythmias: Avoid propafenone in patients with non-life-threatening ventricular arrhythmias. Cardiovascular effects: Has proarrhythmic effect; evaluate patients electrocardiographically and clinically prior to and during therapy to determine if response supports continued use. CHF: Since propafenone exerts beta blockade and a negative inotropic effect, fully compensate patients before giving propafenone. Hepatic dysfunction: Use with caution. Renal dysfunction: Use with caution.

OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, somnolence, bradycardia, intra-atrial and intraventricular conduction disturbances, convulsions, high-grade ventricular arrhythmias

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.